Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZD 4573 is an inhibitor of cyclin-dependent kinase 9 (Cdk9; IC50 = 14 nM).1 It is selective for Cdk9 over Cdk1, Cdk7, Cdk4/6, and Cdk2 (IC50s = 370, 1,100, 1,100, and >10,000 nM, respectively). AZD 4573 (100 nM) induces apoptosis in MV4-11 acute myeloid leukemia (AML) cells. In vivo, AZD 4573 (15 mg/kg every other day), in combination with the Bcl-2 inhibitor venetoclax (ABT-199; Item No. 16233), reduces tumor volumes in SU-DHL-4 B cell lymphoma and OCI-AML-3 AML mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. AZD4573 Is a highly selective CDK9 inhibitor that suppresses MCL-